Drizalma Sprinkle Shortage: What Providers and Prescribers Need to Know in 2026

This article provides a clinical and logistical update on Drizalma Sprinkle (duloxetine delayed-release sprinkle capsules) for prescribers and pharmacists navigating availability challenges in 2026. While the formal shortage has been resolved, the single-source nature of this formulation means that supply-related questions continue to arise in practice. Understanding the landscape helps you proactively manage your patients' treatment continuity.

Clinical Background: What Makes Drizalma Sprinkle Unique

Drizalma Sprinkle is the only brand-name duloxetine formulation specifically designed for patients who cannot swallow intact capsules. The enteric-coated pellets inside the capsule can be opened and administered in one of two ways:

• Sprinkled onto 1 tablespoon of applesauce and swallowed immediately without chewing
• Added to an all-plastic catheter tip syringe with 50 mL of water, shaken for 10 seconds, and administered via a 12 French or larger nasogastric tube

Standard duloxetine delayed-release capsules (Cymbalta and generics) are NOT designed to be opened. Opening them disrupts the enteric coating and can alter the drug's release kinetics and absorption, potentially reducing efficacy or increasing side effects. This is a critical clinical distinction that determines whether a direct substitution is appropriate.

Drizalma Sprinkle is approved for:

• Major Depressive Disorder (adults)
• Generalized Anxiety Disorder (adults and children 7+)
• Diabetic Peripheral Neuropathy (adults)
• Fibromyalgia (adults)
• Chronic Musculoskeletal Pain (adults)

Shortage History and Current Supply Status

The 2023 shortage originated from manufacturing disruptions at Sun Pharma's facility in Mohali, India. Sun Pharma is the sole manufacturer and distributor of this formulation (distributed through Sun Pharmaceutical Industries, Inc., Cranbury, NJ). The ASHP formally listed Drizalma Sprinkle in shortage during 2023, with the situation persisting into early 2024.

Sun Pharma relaunched production in mid-2024. As of early 2026, the formal shortage is resolved and all four strengths (20 mg, 30 mg, 40 mg, 60 mg) are in production. However, the supply chain vulnerability inherent to a single-source product remains. Providers should treat this as a medication with ongoing, low-level availability risk.

Prescribing Strategies to Minimize Fill Difficulties

• Prescribe 90-day supplies when clinically appropriate. Larger supplies reduce fill frequency and provide a buffer if the medication becomes temporarily unavailable.
• Consider whether the sprinkle feature is truly necessary. For patients who have transitioned to being able to swallow tablets or capsules, reassessing whether generic duloxetine DR capsules would be appropriate reduces the single-source dependency.
• Document medical necessity for the sprinkle formulation. Insurance prior authorization often requires documented clinical justification. Clear documentation of the patient's inability to swallow standard capsules can expedite coverage approvals.
• Have an alternative plan documented. Discuss with your patient — in advance — what alternative would be appropriate if Drizalma Sprinkle becomes unavailable. Document this in the chart so any covering provider can act quickly.

Clinical Alternative Strategies When Drizalma Sprinkle Is Unavailable

When Drizalma Sprinkle is unavailable or inaccessible, the appropriate alternative depends on the clinical indication and the patient's ability to swallow:

• Patient can now swallow intact capsules: Transition to generic duloxetine delayed-release capsules (20 mg, 30 mg, or 60 mg). Bioequivalent; no dose adjustment typically needed. Much lower cost.
• Patient cannot swallow, needs sprinkle: Venlafaxine XR capsules (Effexor XR generics) can be opened and contents sprinkled onto applesauce. Not FDA-approved for pain indications, but this is an option for MDD/GAD. Consider compounding pharmacy for a liquid duloxetine suspension if venlafaxine is not appropriate.
• Fibromyalgia indication: Milnacipran (Savella) is the most appropriate SNRI alternative. Pregabalin (Lyrica) or gabapentin are FDA-approved or guideline-supported alternatives via a different mechanism.
• Diabetic neuropathy: Pregabalin (Lyrica), gabapentin, or tricyclic antidepressants (with appropriate monitoring) are established alternatives per ADA guidelines.

Insurance and Prior Authorization Considerations

Drizalma Sprinkle is a brand-name-only medication and is typically placed on Tier 3 or higher on most formularies. Most plans require:

• Prior authorization documenting medical necessity for the sprinkle formulation
• Step therapy: documented trial of generic duloxetine capsules first (if patient can swallow), or documented clinical contraindication
• Annual PA renewals in many plans

How medfinder Helps Your Patients

When patients report difficulty finding Drizalma Sprinkle, a practical immediate step is referring them to medfinder. medfinder calls pharmacies near the patient to find which ones have the specific medication and strength in stock, then texts results to the patient. This eliminates the time patients spend calling pharmacies themselves and helps them locate supply quickly, minimizing treatment interruptions. Learn more about medfinder for providers.

Key Takeaways for Providers

• The formal Drizalma Sprinkle shortage is resolved as of 2026, but single-source supply risk persists
• Standard generic duloxetine capsules are NOT appropriate substitutes for patients who clinically require the sprinkle formulation
• Venlafaxine XR capsules can be opened and sprinkled — a useful backup for MDD/GAD patients
• Document medical necessity for PA approval; prescribe 90-day supplies when possible
• For patient-facing communication, direct patients to our Drizalma Sprinkle shortage patient update